幽門螺桿菌感染治療對(duì)慢性阻塞性肺疾病患者臨床特征的影響
[Abstract]:Objective to investigate the effect of Helicobacter pylori (Hp) infection on the clinical characteristics of (COPD) patients with chronic obstructive pulmonary disease (COPD), and to compare the difference of Hp eradication rate between different treatments. Methods the clinical data of 98 patients with COPD complicated with Hp infection from January 2010 to January 2013 were selected. 34 patients in group A, 34 patients in group B, 34 patients in group C, 30 patients in group A and 30 patients in group B were treated with eradication therapy for Hp infection. Group A was treated with clarithromycin combined therapy and group B was treated with moxifloxacin tetralogy. To compare the eradication rate of Hp in group A and B, and to record and compare the respiratory function scale (Borg),) pulmonary function score, the score of S-Gorge quality of life (QOL) and the times of acute attack during follow-up. Results the eradication rate of Hp in group A and group B was 50.000 and 88.24, respectively, the difference was statistically significant (P0.05), the scores of pulmonary function and motor tolerance were better than those of patients without eradication 12 months after eradication treatment. The difference was statistically significant (P0.05), the scores of S-Gorge quality of life after 12 months of eradication treatment were (33.95 鹵5.88) and (1.19 鹵0.78), respectively, which were better than those of patients without eradication (43.48 鹵6.12), (2.03 鹵0.93), the difference was statistically significant (P0.05). Conclusion after Hp infection is eradicated in patients with COPD, respiratory function and exercise tolerance can be improved and the incidence of acute attack can be reduced, and the quality of life can be improved by moxifloxacin tetralogy, which is more effective than moxifloxacin in the eradication of Hp in COPD patients.
【作者單位】: 山東大學(xué)附屬臨沂市人民醫(yī)院消化內(nèi)一科;
【基金】:山東省衛(wèi)生廳基金資助項(xiàng)目(SW-2010B027)
【分類號(hào)】:R563.9
【參考文獻(xiàn)】
相關(guān)期刊論文 前1條
1 王靜;王江濱;李立;;慢性阻塞性肺病患者幽門螺桿菌感染狀況及其致病危險(xiǎn)性分析[J];中國(guó)老年學(xué)雜志;2010年05期
【共引文獻(xiàn)】
相關(guān)期刊論文 前6條
1 王順瑩;;慢性阻塞性肺病患者HP感染狀況及致病性研究[J];中國(guó)醫(yī)藥導(dǎo)刊;2012年05期
2 譚小玉;黎雨;陳俊健;;慢性阻塞性肺疾病患者幽門螺桿菌感染狀況及其對(duì)肺功能的影響[J];內(nèi)科;2014年03期
3 侯俊榮;池麗英;;慢性阻塞性肺病幽門螺桿菌感染狀況及其致病危險(xiǎn)性分析[J];海南醫(yī)學(xué)院學(xué)報(bào);2014年08期
4 譚小玉;陳俊健;黎雨;方妮;;慢性阻塞性肺疾病患者幽門螺桿菌感染及其血沉及超敏C反應(yīng)蛋白分析研究[J];內(nèi)科;2014年04期
5 余闐;胡玲;陳霞;王瑩;楊煒;李偉銘;;幽門螺桿菌感染與慢性阻塞性肺疾病關(guān)系探討[J];四川醫(yī)學(xué);2015年02期
6 楊柳;張淑華;;新化合物對(duì)幽門螺桿菌的抗菌活性[J];中國(guó)老年學(xué)雜志;2012年02期
【相似文獻(xiàn)】
相關(guān)期刊論文 前10條
1 李杰;劉惟優(yōu);賴慶文;曾治平;劉建生;;慢性阻塞性肺疾病患者的電話隨訪干預(yù)與肺康復(fù)[J];贛南醫(yī)學(xué)院學(xué)報(bào);2011年06期
2 黃慶田;;中西醫(yī)結(jié)合預(yù)防慢性阻塞性肺疾病急性發(fā)作的臨床觀察[J];廣西中醫(yī)藥;2011年05期
3 張燕玲,董碧蓉,岳冀蓉;慢性阻塞性肺病穩(wěn)定期的治療方法[J];中國(guó)循證醫(yī)學(xué);2002年01期
4 郭銀燕;劉茜;陳凡;彭家先;;沐舒坦片治療慢性阻塞性肺疾病的療效觀察[J];中國(guó)民康醫(yī)學(xué);2008年19期
5 李曉康;羅丹;;泛福舒對(duì)預(yù)防慢性阻塞性肺病急性發(fā)作的意義[J];現(xiàn)代預(yù)防醫(yī)學(xué);2006年08期
6 袁義;王娟;;慢性阻塞性肺疾病患者合并抑郁障礙的研究[J];臨床肺科雜志;2014年01期
7 魏光晨,周玉發(fā),賈心紅;應(yīng)用個(gè)體化營(yíng)養(yǎng)方案對(duì)COPD患者病情影響的研究[J];泰山醫(yī)學(xué)院學(xué)報(bào);2004年06期
8 魯芬;楊炯;;大環(huán)內(nèi)酯類抗生素治療慢性阻塞性肺疾病的臨床觀察[J];吉林醫(yī)學(xué);2010年07期
9 婁培安;余加席;張雷;陳培培;張寧;張莉;韓令才;李剛;姜珊;;健康管理對(duì)慢性阻塞性肺疾病患者脆弱性改變的作用[J];中華全科醫(yī)學(xué);2011年06期
10 周芳;;中西醫(yī)結(jié)合治療60例慢性阻塞性肺疾病臨床觀察[J];基層醫(yī)學(xué)論壇;2013年01期
,本文編號(hào):2206772
本文鏈接:http://sikaile.net/yixuelunwen/huxijib/2206772.html